Clinical Report: Efficacy and Safety of Sequential Gemcitabine and Docetaxel

Overview

This systematic review and meta-analysis evaluated the efficacy and safety of intravesical sequential gemcitabine and docetaxel (GEM/DOCE) in treating high-risk non-muscle-invasive bladder cancer (NMIBC).

Background

Non-muscle-invasive bladder cancer (NMIBC) presents a significant clinical challenge due to its high recurrence rates and potential for progression. Bacillus Calmette–Guérin (BCG) therapy, the standard treatment, faces limitations including treatment failure and global shortages.

Data Highlights

Key Findings

• The pooled 12-month recurrence-free survival (RFS) was 73.75%.
• BCG-naïve patients had a significantly higher 12-month RFS of 82.50% compared to 60.00% in BCG-failure patients (p < 0.001).
• High-grade recurrence-free survival (HG-RFS) was 75.78% overall, with BCG-naïve patients showing 84.09% HG-RFS.
• Progression-free survival was reported at 95.57% at 12 months.
• GEM/DOCE was generally well tolerated, with a treatment-related adverse event rate of 52.59%.
• The overall treatment intolerance rate was low at 3.55%.

Clinical Implications

The findings suggest that intravesical GEM/DOCE may be a viable treatment option for high-risk NMIBC patients, particularly those who are BCG-naïve. Clinicians should consider this regimen as part of the treatment strategy for patients with limited responses to BCG therapy.

Conclusion

Intravesical GEM/DOCE demonstrates efficacy and safety profiles in treating high-risk NMIBC.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. fox chase cancer center — Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)
3. the asco post — Gemcitabine Intravesical System Shows High Disease-Free Survival Rates in BCG-Unresponsive Papillary-Only NMIBC
4. The ASCO Post — Gemcitabine Intravesical System Shows High Disease-Free Survival Rates in BCG-Unresponsive Papillary-Only NMIBC KEY POINTS
5. Evaluating Initial Therapies for BCG-Naïve Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
6. Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone)
7. Gemcitabine Intravesical System Shows High Disease-Free Survival Rates in BCG-Unresponsive Papillary-Only NMIBC
8. FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
9. https://d56bochluxqnz.cloudfront.net/documents/EAU-Guidelines-on-Non-muscle-Invasive-Bladder-Cancer-2025.pdf
10. Efficacy and Toxicity in Scheduled Intravesical Gemcitabine Versus Bacillus Calmette–Guérin for Bladder Cancer: A Systematic Review and Meta-Analysis
11. IP02-11 BACILLUS CALMETTE-GUÉRIN VERSUS SEQUENTIAL GEMCITABINE AND DOCETAXEL FOR TA HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER | Journal of Urology